{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:49:12Z","timestamp":1790754552911,"version":"4.1.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,8,16]],"date-time":"2013-08-16T00:00:00Z","timestamp":1376611200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s11920-013-0393-0","type":"journal-article","created":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T15:54:01Z","timestamp":1376582041000},"source":"Crossref","is-referenced-by-count":43,"title":["Psychopharmacology in Psycho-oncology"],"prefix":"10.1007","volume":"15","author":[{"given":"Rosangela","family":"Caruso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giulia","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Riba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,16]]},"reference":[{"key":"393_CR1","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/pon.3154","volume":"21","author":"L Grassi","year":"2012","unstructured":"Grassi L, Watson M, on behalf of the IPOS Federation of Psycho-Oncology Societies\u2019 co-authors. Psychosocial care in cancer: an overview of psychosocial programmes and national cancer plans of countries within the International Federation of Psycho-Oncology Societies. Psychooncology. 2012;21:1027\u201333.","journal-title":"Psychooncology"},{"key":"393_CR2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/pon.1978","volume":"20","author":"J Holland","year":"2011","unstructured":"Holland J, Watson M, Dunn J. The IPOS New International Standard of Quality Cancer Care: integrating the psychosocial domain into routine care. Psychooncology. 2011;20:677\u201380.","journal-title":"Psychooncology"},{"key":"393_CR3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/9781119941101.ch9","volume-title":"Clinical Psycho-Oncology: an international perspective","author":"SM Thekdi","year":"2012","unstructured":"Thekdi SM, Irarrazaval ME, Dunn L. Psychopharmacological interventions. In: Grassi L, Riba M, editors. Clinical Psycho-Oncology: an international perspective. Wiley: Chichester; 2012. p. 109\u201326."},{"key":"393_CR4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1470-2045(11)70002-X","volume":"12","author":"AJ Mitchell","year":"2011","unstructured":"\u2022\u2022 Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12:160\u201374. This is a meta-analysis of the most significant studies in the field of oncology, hematology, and palliative care regarding the prevalence of psychiatric disorders among cancer patients.","journal-title":"Lancet Oncol."},{"key":"393_CR5","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/annonc\/mdp515","volume":"21","author":"S Singer","year":"2010","unstructured":"\u2022 Singer S, Das-Munshi J, Br\u00e4hler E. Prevalence of mental health conditions in cancer patients in acute care\u2013a meta-analysis. Ann Oncol. 2010;21:925\u201330. This is a study evaluating the prevalence of psychiatric disorders in cancer inpatients in acute care.","journal-title":"Ann Oncol"},{"key":"393_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pon.1929","volume":"21","author":"P Brocken","year":"2012","unstructured":"Brocken P, Prins JB, Dekhuijzen PN, van der Heijden HF. The faster the better?\u2014A systematic review on distress in the diagnostic phase of suspected cancer, and the influence of rapid diagnostic pathways. Psychooncology. 2012;21:1\u201310.","journal-title":"Psychooncology."},{"key":"393_CR7","volume-title":"Delirium: acute confusional states in palliative medicine","author":"A Caraceni","year":"2011","unstructured":"Caraceni A, Grassi L. Delirium: acute confusional states in palliative medicine. 2nd ed. Oxford: Oxford University Press; 2011.","edition":"2"},{"key":"393_CR8","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/1097-0142(197911)44:5<1919::AID-CNCR2820440555>3.0.CO;2-T","volume":"44","author":"LR Derogatis","year":"1979","unstructured":"Derogatis LR, Feldstein M, Morrow G, et al. A survey of psychotropic drug prescriptions in an oncology population. Cancer. 1979;44:1919\u201329.","journal-title":"Cancer"},{"key":"393_CR9","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/1097-0142(19900215)65:4<1048::AID-CNCR2820650434>3.0.CO;2-N","volume":"65","author":"FC Stiefel","year":"1990","unstructured":"Stiefel FC, Kornblith AB, Holland JC. Changes in prescription patterns of psychotropic drugs for cancer patients during a 10-year period. Cancer. 1990;65:1048\u201353.","journal-title":"Cancer"},{"key":"393_CR10","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/bjc.2012.364","volume":"107","author":"F Desplenter","year":"2012","unstructured":"\u2022 Desplenter F, Bond C, Watson M, Burton C, Murchie P, Lee AJ, et al. Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case\u2013control study. Br J Cancer. 2012;107:1644\u201351. The study quantified the higher incidence of new emotional distress in cancer patients in the first year post diagnosis and the use of psychotropic drugs.","journal-title":"Br J Cancer"},{"key":"393_CR11","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00520-011-1242-5","volume":"20","author":"GH Bock De","year":"2012","unstructured":"De Bock GH, Musters RF, Bos HJ, Schr\u00f6der CP, Mourits MJ, de Jong-van den Berg LT. Psychotropic medication during endocrine treatment for breast cancer. Support Care Cancer. 2012;20:1533\u201340.","journal-title":"Support Care Cancer."},{"key":"393_CR12","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/pon.3056","volume":"22","author":"CG Ng","year":"2013","unstructured":"Ng CG, Boks MP, Smeets HM, Zainal NZ, de Wit NJ. Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands. Psychooncology. 2013;22:762\u20137.","journal-title":"Psychooncology."},{"key":"393_CR13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jpainsymman.2011.05.010","volume":"43","author":"C Farriols","year":"2012","unstructured":"Farriols C, Ferr\u00e1ndez O, Planas J, et al. Changes in the prescription of psychotropic drugs in the palliative care of advanced cancer patients over a seven-year period. J Pain Symptom Manage. 2012;43:945\u201352.","journal-title":"J Pain Symptom Manage."},{"key":"393_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2010.07.034","volume":"131","author":"CG Ng","year":"2011","unstructured":"Ng CG, Boks MP, Zainal NZ, de Wit NJ. The prevalence and pharmacotherapy of depression in cancer patients. J Affect Disord. 2011;131:1\u20137.","journal-title":"J Affect Disord"},{"key":"393_CR15","first-page":"151","volume-title":"Depression and cancer","author":"L Grassi","year":"2011","unstructured":"Grassi L, Nanni MG, Uchitomi Y, Riba M. Pharmacotherapy of depression in people with cancer. In: Kissane DW, Maj M, Sartorius N, editors. Depression and cancer. Chichester: Wiley; 2011. p. 151\u201376."},{"key":"393_CR16","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/jnci\/djs256","volume":"104","author":"SL Hart","year":"2012","unstructured":"\u2022 Hart SL, Hoyt MA, Diefenbach M, et al. Meta-analysis of efficacy of interventions for elevated depressive symptoms in adults diagnosed with cancer. J Natl Cancer Inst. 2012;104:990\u20131004. This study suggests that psychological and pharmacologic approaches can be targeted productively toward cancer patients with elevated depressive symptoms.","journal-title":"J Natl Cancer Inst."},{"key":"393_CR17","doi-asserted-by":"crossref","unstructured":"\u2022 Laoutidis ZG. Mathiak K- Antidepressants in the treatment of depression\/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry. 2013;13:140. doi: 10.1186\/1471-244X-13-140 . This meta-analysis suggests that antidepressants can be effective in treating depressive symptoms besides clinical depression.","DOI":"10.1186\/1471-244X-13-140"},{"key":"393_CR18","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ejca.2010.11.027","volume":"47","author":"L Rayner","year":"2011","unstructured":"Rayner L, Price A, Hotopf M, Higginson IJ. The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur J Cancer. 2011;47:702\u201312.","journal-title":"Eur J Cancer"},{"key":"393_CR19","author":"JL Jongen","year":"2013","unstructured":"Jongen JL, Huijsman ML, Jessurun J, et al. The evidence for pharmacologic treatment of neuropathic cancer pain: beneficial and adverse effects. J Pain Symptom Manage. 2013. doi: 10.1016\/j.jpainsymman.2012.10.230 [Epub ahead of print].","journal-title":"J Pain Symptom Manage."},{"key":"393_CR20","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.2165\/0003495-200868180-00007","volume":"68","author":"B Verdu","year":"2008","unstructured":"Verdu B, Decosterd I, Buclin T, Stiefel F, Berney A. Antidepressants for the treatment of chronic pain. Drugs. 2008;68:2611\u201332.","journal-title":"Drugs"},{"key":"393_CR21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1177\/0269216310378546","volume":"25","author":"MI Bennett","year":"2011","unstructured":"Bennett MI. Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review. Palliat Med. 2011;25:553\u201339.","journal-title":"Palliat Med."},{"issue":"Supplement 7","key":"393_CR22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/annonc\/mds233","volume":"23","author":"C Ripamonti","year":"2012","unstructured":"Ripamonti C, Santini D, Maranzano E, Berti M, Roila F, on behalf of the ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncology. 2012;23(Supplement 7):139\u201354.","journal-title":"Ann Oncology"},{"key":"393_CR23","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EM Smith","year":"2013","unstructured":"Smith EM, Pang H, Cirrincione C, et al. Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359\u201367.","journal-title":"JAMA."},{"key":"393_CR24","first-page":"1805","volume":"32","author":"H Matsuoka","year":"2012","unstructured":"Matsuoka H, Makimura C, Koyama A, Otsuka M, Okamoto W, et al. Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. Anticancer Res. 2012;32:1805\u20139.","journal-title":"Anticancer Res"},{"key":"393_CR25","doi-asserted-by":"crossref","unstructured":"Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012.","DOI":"10.1002\/14651858.CD008242.pub2"},{"key":"393_CR26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2354.2006.00760.x","volume":"16","author":"RE Kast","year":"2007","unstructured":"Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl). 2007;16:351\u20134.","journal-title":"Eur J Cancer Care (Engl)."},{"key":"393_CR27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/1049909109345685","volume":"27","author":"RP Riechelmann","year":"2010","unstructured":"Riechelmann RP, Burman D, Tannock IF, Rodin G, Zimmermann C. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care. 2010;27:106\u201310.","journal-title":"Am J Hosp Palliat Care."},{"key":"393_CR28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1200\/JCO.2001.19.3.895","volume":"19","author":"J Savard","year":"2001","unstructured":"Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol. 2001;19:895\u2013908.","journal-title":"J Clin Oncol"},{"key":"393_CR29","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.sleep.2012.06.001","volume":"13","author":"OG Palesh","year":"2012","unstructured":"Palesh OG, Mustian KM, Peppone LJ, Janelsins M, et al. Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: a trial from the University of Rochester Cancer Center Community Clinical Oncology Program. Sleep Med. 2012;13:1184\u201390.","journal-title":"Sleep Med."},{"key":"393_CR30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/1049909112452334","volume":"30","author":"H Tanimukai","year":"2013","unstructured":"Tanimukai H, Murai T, Okazaki N, Matsuda Y, et al. An observational study of insomnia and nightmare treated with trazodone in patients with advanced cancer. Am J Hosp Palliat Care. 2013;30:359\u201362.","journal-title":"Am J Hosp Palliat Care."},{"key":"393_CR31","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1634\/theoncologist.2011-0174","volume":"16","author":"PK Morrow","year":"2011","unstructured":"Morrow PK, Mattair DN, Hortobagyi GN. Hot flashes: a review of pathophysiology and treatment modalities. Oncologist. 2011;16:1658\u201364.","journal-title":"Oncologist"},{"key":"393_CR32","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1176\/appi.ajp.2008.08040482","volume":"165","author":"NL Henry","year":"2008","unstructured":"Henry NL, Stearns V, Flockhart DA, Hayes DF, Riba M. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry. 2008;165:1251\u20135.","journal-title":"Am J Psychiatry"},{"key":"393_CR33","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.4088\/JCP.08r04856blu","volume":"70","author":"JE Desmarais","year":"2009","unstructured":"Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009;70:1688\u201397.","journal-title":"J Clin Psychiatry."},{"key":"393_CR34","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2174\/138920011795713706","volume":"12","author":"F Caraci","year":"2011","unstructured":"\u2022 Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. Curr Drug Metab. 2011;12:570\u20137. The article provides an updated review of clinically relevant metabolic drug interactions between selected anticancer drugs, SSRIs, and Hypericum extract, showing the inhibiting effect on one or more cytochrome P450 isoenzymes (CYPs), inducing effect on CYP3A4 and P-glycoprotein (P-gp), with reduction of plasma concentrations of anticancer durgs (e.g., imatinib, irinotecan and docetaxel).","journal-title":"Curr Drug Metab."},{"key":"393_CR35","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00520-013-1732-8","volume":"21","author":"S L\u2019Esp\u00e9rance","year":"2013","unstructured":"L\u2019Esp\u00e9rance S, Frenette S, Dionne A, Dionne JY. Comit\u00e9 de l\u2019\u00e9volution des pratiques en oncologie (CEPO) Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer. 2013;21:1461\u201374.","journal-title":"Support Care Cancer."},{"key":"393_CR36","doi-asserted-by":"crossref","unstructured":"Binkhorst L, Mathijssen RH, van Herk-Sukel MP et al. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat. 2013.","DOI":"10.1007\/s10549-013-2585-z"},{"key":"393_CR37","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.6004\/jnccn.2007.0089","volume":"5","author":"W Breitbart","year":"2007","unstructured":"\u2022\u2022 Breitbart W, Alici-Evcimen Y. Update on psychotropic medications for cancer-related fatigue. J Natl Compr Canc Netw. 2007;5:1081\u201391. The paper reviews the most important psychotropic drugs that have been studied for cancer-related fatigue, such as psychostimulants, wakefulness-promoting agents, and antidepressants. It also indicates that, studies are currently limited and that randomized, placebo-controlled trials with specific agents are needed.","journal-title":"J Natl Compr Canc Netw"},{"key":"393_CR38","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1093\/jnci\/djn250","volume":"100","author":"O Minton","year":"2008","unstructured":"Minton O, Richardson A, Sharpe M, Hotopf M, Stone P. A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst. 2008;100:1155\u201366.","journal-title":"J Natl Cancer Inst"},{"key":"393_CR39","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3109\/00048674.2011.595686","volume":"45","author":"S Dodd","year":"2011","unstructured":"Dodd S, Malhi GS, Tiller J, et al. A consensus statement for safety monitoring guidelines of treatments for major depressive disorder. Austr New Zeal J Psychiatry. 2011;45:712\u201325.","journal-title":"Austr New Zeal J Psychiatry"},{"key":"393_CR40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s005200050021","volume":"8","author":"C Mazzocato","year":"2000","unstructured":"Mazzocato C, Stiefel F, Buclin T, Berney A. Psychopharmacology in supportive care of cancer: a review for the clinician: II. Neuroleptics. Support Care Cancer. 2000;8:89\u201397.","journal-title":"Support Care Cancer."},{"key":"393_CR41","volume":"11","author":"B Candy","year":"2012","unstructured":"Candy B, Jackson KC, Jones L, Leurent B, Tookman A, King M. Drug therapy for delirium in terminally ill adult patients. Cochrane Database Syst Rev. 2012;11, CD004770.","journal-title":"Cochrane Database Syst Rev."},{"key":"393_CR42","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1200\/JCO.2011.39.8784","volume":"30","author":"W Breitbart","year":"2012","unstructured":"\u2022\u2022 Breitbart W, Alici Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol. 2012;30:1206\u201314. This article presents evidence-based recommendations based on the results of pharmacologic and nonpharmacologic studies of the treatment and prevention of delirium.","journal-title":"J Clin Oncol"},{"key":"393_CR43","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1440-1819.2012.02346.x","volume":"66","author":"Y Kishi","year":"2012","unstructured":"Kishi Y, Kato M, Okuyama T, Thurber S. Treatment of delirium with risperidone in cancer patients. Psychiatry Clin Neurosci. 2012;66:411\u20137.","journal-title":"Psychiatry Clin Neurosci."},{"key":"393_CR44","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jpainsymman.2010.02.017","volume":"40","author":"A Elsayem","year":"2010","unstructured":"Elsayem A, Bush SH, Munsell MF, Curry 3rd E, Calderon BB, Paraskevopoulos T, et al. Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study. J Pain Symptom Manage. 2010;40:774\u201382.","journal-title":"J Pain Symptom Manage."},{"key":"393_CR45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/082585971102700210","volume":"27","author":"D Hui","year":"2011","unstructured":"Hui D, Reddy A, Palla S, Bruera E. Neuroleptic prescription pattern for delirium in patients with advanced cancer. J Palliat Care. 2011;27:141\u20137.","journal-title":"J Palliat Care."},{"key":"393_CR46","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jpainsymman.2009.07.009","volume":"39","author":"D Hui","year":"2010","unstructured":"Hui D, Bush SH, Gallo LE, Palmer JL, Yennurajalingam S, Bruera E. Neuroleptic dose in the management of delirium in patients with advanced cancer. J Pain Symptom Manage. 2010;39:186\u201396.","journal-title":"J Pain Symptom Manage."},{"key":"393_CR47","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00520-012-1574-9","volume":"21","author":"C Pirri","year":"2013","unstructured":"Pirri C, Bayliss E, Trotter J, Olver IN, Katris P, Drummond P, et al. Nausea still the poor relation in antiemetic therapy? The impact on cancer patients\u2019 quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster. Support Care Cancer. 2013;21:735\u201348.","journal-title":"Support Care Cancer."},{"key":"393_CR48","doi-asserted-by":"crossref","unstructured":"McLean SL, Blenkinsopp A, Bennett MI. Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. J Pain Palliat Care Pharmacother. 2013;27:132\u20135.","DOI":"10.3109\/15360288.2013.782937"},{"key":"393_CR49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1049909110361228","volume":"27","author":"SK Ang","year":"2010","unstructured":"Ang SK, Shoemaker LK, Davis MP. Nausea and vomiting in advanced cancer. Am J Hosp Palliat Care. 2010;27:219\u201325.","journal-title":"Am J Hosp Palliat Care."},{"key":"393_CR50","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jpainsymman.2011.10.023","volume":"44","author":"K Kaneishi","year":"2012","unstructured":"Kaneishi K, Kawabata M, Morita T. Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction. J Pain Symptom Manage. 2012;44:604\u20137.","journal-title":"J Pain Symptom Manage."},{"key":"393_CR51","doi-asserted-by":"crossref","unstructured":"Thomson K, Henry B. Oncology clinical challenges: caring for patients with preexisting psychiatric illness. Clin J Oncol Nurs. 2012;16:471\u201380","DOI":"10.1188\/12.CJON.471-480"},{"key":"393_CR52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ncl.2011.09.004","volume":"30","author":"KJ Baldwin","year":"2012","unstructured":"Baldwin KJ, Zivkovi\u0107 SA, Lieberman FS. Neurologic emergencies in patients who have cancer: diagnosis and management. Neurol Clin. 2012;30:101\u201328.","journal-title":"Neurol Clin"},{"key":"393_CR53","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1592\/phco.30.9.942","volume":"30","author":"RA Lorenz","year":"2010","unstructured":"Lorenz RA, Jackson CW, Saitz M. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacotherapy. 2010;30:942\u201351.","journal-title":"Pharmacotherapy"},{"key":"393_CR54","doi-asserted-by":"crossref","unstructured":"Patkar AA, Pae CU. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs. 2013;27 Suppl 1:29\u201337.","DOI":"10.1007\/s40263-012-0031-0"},{"key":"393_CR55","volume":"5","author":"S Suttajit","year":"2013","unstructured":"Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B. Maneeton N Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev. 2013;5, CD007815. doi: 10.1002\/14651858.CD007815.pub2 .","journal-title":"Cochrane Database Syst Rev."},{"key":"393_CR56","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/NDT.S40554","volume":"9","author":"R Bod\u00e9n","year":"2013","unstructured":"Bod\u00e9n R, Edman G, Reutfors J, Ostenson CG, Osby U. A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. Neuropsychiatr Dis Treat. 2013;9:371\u20137.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"393_CR57","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.seizure.2012.10.009","volume":"22","author":"U Lertxundi","year":"2013","unstructured":"Lertxundi U, Hernandez R, Medrano J, Domingo-Echaburu S, Garc\u00eda M. Aguirre C Antipsychotics and seizures: higher risk with atypicals? Seizure. 2013;22:141\u20133.","journal-title":"Seizure"},{"key":"393_CR58","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hup.1181","volume":"26","author":"PM Nooijen","year":"2011","unstructured":"Nooijen PM, Carvalho F, Flanagan RJ. Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum Psychopharmacol. 2011;26:112\u20139.","journal-title":"Hum Psychopharmacol."},{"issue":"7","key":"393_CR59","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1211\/jpp.58.7.0001","volume":"58","author":"M Murray","year":"2006","unstructured":"Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol. 2006;58(7):871\u201385.","journal-title":"J Pharm Pharmacol"},{"key":"393_CR60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10911-008-9074-8","volume":"13","author":"CV Clevenger","year":"2008","unstructured":"Clevenger CV, Zheng J, Jablonski EM, Galbaugh TM, Fang F. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J Mammary Gland Biol Neoplasia. 2008;13:147\u201356.","journal-title":"J Mammary Gland Biol Neoplasia."},{"key":"393_CR61","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s005200050296","volume":"7","author":"F Stiefel","year":"1999","unstructured":"Stiefel F, Berney A, Mazzocato C. Psychopharmacology in supportive care in cancer: a review for the clinician. I. Benzodiazepines. Support Care Cancer. 1999;7:379\u201385.","journal-title":"Support Care Cancer"},{"key":"393_CR62","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00520-010-0980-0","volume":"19","author":"JA Roscoe","year":"2011","unstructured":"Roscoe JA, Morrow GR, Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer. 2011;19:1533\u20138.","journal-title":"Support Care Cancer."},{"issue":"Suppl 1","key":"393_CR63","first-page":"65","volume":"17","author":"A Testa","year":"2013","unstructured":"Testa A, Giannuzzi R, Sollazzo F, Petrongolo L, Bernardini L. Dain SPsychiatric emergencies (part II): psychiatric disorders coexisting with organic diseases. Eur Rev Med Pharmacol Sci. 2013;17 Suppl 1:65\u201385.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"393_CR64","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/CCM.0b013e318275d014","volume":"41","author":"Y Skrobik","year":"2013","unstructured":"Skrobik Y, Leger C, Cossette M, Michaud V, Turgeon J. Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors. Crit Care Med. 2013;41:999\u20131008.","journal-title":"Crit Care Med"},{"key":"393_CR65","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/jpm.2010.0465","volume":"14","author":"C Costantini","year":"2011","unstructured":"Costantini C, Ale-Ali A. Helsten T Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. J Palliat Med. 2011;14:563\u20136.","journal-title":"J Palliat Med."},{"key":"393_CR66","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/gme.0b013e3181dbee1b","volume":"17","author":"H Joffe","year":"2010","unstructured":"Joffe H, Partridge A, Giobbie-Hurder A, Li X, Habin K, Goss P, et al. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause. 2010;17:908\u201316.","journal-title":"Menopause"},{"key":"393_CR67","volume":"4","author":"A Hirst","year":"2002","unstructured":"Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care. Cochrane Database Syst Rev. 2002;4, CD003346.","journal-title":"Cochrane Database Syst Rev."},{"key":"393_CR68","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(11)61516-X","volume":"379","author":"RF McKnight","year":"2012","unstructured":"McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379:721\u20138.","journal-title":"Lancet"},{"key":"393_CR69","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/bja\/aet208","volume":"111","author":"MT Fallon","year":"2013","unstructured":"\u2022 Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013;111:105\u201311. This review summarizes standard guidelines for the use of anticonvulsants (e.g. pregabalin and gabapentin), antidepressants (e.g. duloxetine and tricyclics), and topical treatments (e.g. capsaicin and lidocaine) in cancer pain, although the authors complain a lack of good-quality clinical trials in cancer-related neuropathic pain.","journal-title":"Br J Anaesth"},{"key":"393_CR70","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s11940-011-0132-y","volume":"13","author":"AA Pruitt","year":"2011","unstructured":"Pruitt AA. Medical management of patients with brain tumors. Curr Treat Options Neurol. 2011;13:413\u201326.","journal-title":"Curr Treat Options Neurol."},{"key":"393_CR71","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/157015912800604470","volume":"10","author":"M Maschio","year":"2012","unstructured":"Maschio M. Brain tumor-related epilepsy. Curr Neuropharmacol. 2012;10:124\u201333.","journal-title":"Curr Neuropharmacol"},{"key":"393_CR72","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1007\/s00415-011-6132-8","volume":"258","author":"M Maschio","year":"2011","unstructured":"Maschio M, Dinapoli L, Mingoia M, Sperati F, et al. Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol. 2011;258:2100\u20134.","journal-title":"J Neurol"},{"key":"393_CR73","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0193-953X(05)70304-X","volume":"19","author":"PS Masand","year":"1996","unstructured":"Masand PS, Tesar GE. Use of stimulants in the medically ill. Psychiatr Clin North Am. 1996;19:515\u201347.","journal-title":"Psychiatr Clin North Am."},{"key":"393_CR74","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s005200050007","volume":"8","author":"J Homsi","year":"2000","unstructured":"Homsi J, Walsh D, Nelson KA. Psychostimulants in supportive care. Support Care Cancer. 2000;8:385\u201397.","journal-title":"Support Care Cancer."},{"key":"393_CR75","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/SPC.0b013e3283462ff3","volume":"5","author":"MA Portela","year":"2011","unstructured":"\u2022 Portela MA, Rubiales AS, Centeno C. The use of psychostimulants in cancer patients. Curr Opin Support Palliat Care. 2011;5:164\u20138. This article reviews the most recent studies that examine the efficacy of psychostimulants for the relief of symptoms such as asthenia and depression in cancer patients.","journal-title":"Curr Opin Support Palliat Care."},{"key":"393_CR76","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jpainsymman.2010.06.020","volume":"41","author":"O Minton","year":"2011","unstructured":"\u2022 Minton O, Richardson A, Sharpe M, Hotopf M, Stone PC. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manage. 2011;41:761\u20137. This article summarizes the increasing evidence for the use of psychostimulants, particularly methylphenidate, in the treatment of cancer-related fatigue.","journal-title":"J Pain Symptom Manage."},{"key":"393_CR77","doi-asserted-by":"crossref","unstructured":"\u2022 Breitbart W, Alici Y. Psychostimulants for cancer-related fatigue. J Natl Compr Canc Netw. 2010;8:933\u201342. This article presents a comprehensive review of the use of psychostimulant agents for fatigue among patients with cancer, including an overview of the clinical trials with psychostimulants and of the clinical guidelines available for treatment of cancer-related fatigue.","DOI":"10.6004\/jnccn.2010.0068"},{"key":"393_CR78","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1188\/11.CJON.607-615","volume":"15","author":"D Ah Von","year":"2011","unstructured":"Von Ah D, Jansen C, Allen DH, Schiavone RM, Wulff J. Putting evidence into practice: evidence-based interventions for cancer and cancer treatment-related cognitive impairment. Clin J Oncol Nurs. 2011;15:607\u201315.","journal-title":"Clin J Oncol Nurs"},{"key":"393_CR79","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/era.11.202","volume":"12","author":"K Gehring","year":"2012","unstructured":"Gehring K, Roukema JA, Sitskoorn MM. Review of recent studies on interventions for cognitive deficits in patients with cancer. Expert Rev Anticancer Ther. 2012;12:255\u201369.","journal-title":"Expert Rev Anticancer Ther"},{"key":"393_CR80","doi-asserted-by":"crossref","first-page":"932","DOI":"10.7150\/ijms.5708","volume":"10","author":"M Zafra-Ceres","year":"2013","unstructured":"Zafra-Ceres M, de Haro T, Farez-Vidal E, Blancas I, Bandres F, de Due\u00f1as EM, et al. Influence of CYP2D6 Polymorphisms on Serum Levels of Tamoxifen Metabolites in Spanish Women with Breast Cancer. Int J Med Sci. 2013;10:932\u20137.","journal-title":"Int J Med Sci."},{"key":"393_CR81","doi-asserted-by":"crossref","unstructured":"Garland SN, Valentine D, Desai K, Li S, Langer C, Evans T, Mao JJ. Complementary and Alternative Medicine (CAM) use and benefit finding among cancer patients. J Altern Complement Med. 2013. doi: 10.1089\/acm.2012.0964 .","DOI":"10.1089\/acm.2012.0964"}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-013-0393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11920-013-0393-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-013-0393-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T00:35:03Z","timestamp":1596328503000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11920-013-0393-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,16]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["393"],"URL":"https:\/\/doi.org\/10.1007\/s11920-013-0393-0","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,16]]},"article-number":"393"}}